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Genetic Influences on the Dynamics of Pain and Affect in
Fibromyalgia
Patrick H. Finan, Alex J. Zautra, Mary C. Davis, and Kathryn Lemery-Chalfant
Arizona State University, Jonathan Covault & Howard Tennen, University of Connecticut School
of Medicine
Abstract
Objective—The purpose of the present investigation was to determine if variation in the
catechol-O-methyltransferase (COMT) and mu-opioid receptor (OPRM1) genes is associated with
pain-related positive affective regulation in fibromyalgia (FM).
Design—Forty-six female FM patients completed an electronic diary that included daily
assessments of positive affect and pain. Between- and within-person analyses were conducted with
multilevel modeling.
Main Outcome Measure—Daily positive affect was the primary outcome measure.
Results—Analyses revealed a significant gene × experience interaction for COMT, such that
individuals with met/met genotype experienced a greater decline in positive affect on days when
pain was elevated than did either val/met or val/val individuals. This finding supports a role for
catecholamines in positive affective reactivity to FM pain. A gene × experience interaction for
OPRM1 also emerged, indicating that individuals with at least one asp40 allele maintained greater
positive affect despite elevations in daily pain than those homozygous for the asn40 allele. This
finding may be explained by the asp40 allele’s role in reward processing.
Conclusions—Together, the findings offer researchers ample reason to further investigate the
contribution of the catecholamine and opioid systems, and their associated genomic variants, to
the still poorly understood experience of FM.
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Introduction
Fibromyalgia (FM) is a chronic musculoskeletal disorder characterized by widespread pain,
fatigue, and a variety of other comorbid physiological and psychological conditions
(Thieme, Turk, & Flor, 2004; Wolfe, Smyth, Yunus et al., 1990). Recent research has
identified a deficit in positive affect (PA) among FM patients, relative to other chronic pain
groups, as a distinctive feature characteristic of the disorder (Finan, Zautra, & Davis, 2009;
Zautra, Fasman, Reich et al., 2005). In the absence of PA, FM patients may be more
vulnerable to the harmful effects of pain on well-being (Zautra, Johnson, & Davis, 2005).
Despite these findings, there is still considerable variability in the symptom presentation of
FM. In the current study, we sought to identify genetic factors that may contribute to
different patterns of positive affective reactivity to pain within the FM population.
In the exploration of the etiopathology of FM, researchers have increasingly shifted focus to
the role of genetics. Interindividual differences in pain sensitivity are often reported to be
substantially greater than intraindividual differences, and so a genetic approach provides an
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opportunity to target biologically latent sources of that variation (Mogil, 1999). Further,
evidence for a strong familial aggregation of FM has led researchers to similarly conclude
that genetic variation may help explain part of its complex symptom presentation. As such,
the focus of research on FM has shifted to a variety of genomic variants (Buskila & Sarzi-
Puttini, 2006; Limer, Nicholl, Thomson, & McBeth, 2008). The majority of pain-related
candidate gene studies have measured phenotypes of pain sensitivity, threshold, and
tolerance. However, few have explored affect and affective reactivity to pain (e.g., Zubieta
et al., 2003), and none have done so within the FM population. Two genes with functional
single nucleotide polymorphisms (SNPs) have emerged as particularly attractive candidates
for the study of the dynamic relations between pain and affect in FM: the catechol-O-
methyltransferase gene (COMT/val158met) and the μ-opioid receptor gene (OPRM1/
asn40asp). Both the catecholaminergic and opioidergic systems, in which COMT and
OPRM1, respectively, have regulatory roles, are intricately involved in the dual processing
of pain and affect (Price, 2000; Smolka, Schumann, Wrase et al., 2005; Zubieta et al., 2003).
The COMT gene codes for an enzyme that facilitates the degradation of the catecholamine
neurotransmitters epinephrine, norepinephrine, and dopamine (Li, Warsh, & Godse, 1984).
Individuals homozygous for the val158allele of the val158met polymorphism have a three to
four-fold increase in enzymatic activity compared to those homozygous for met158 as a
result of changes in thermostability of the enzyme (Spielman & Weinshilboum, 1981). The
heterozygous genotype (val/met) produces intermediate enzymatic activity, indicating that
the alleles are codominant. There is evidence to support a role for the met158 allele as a
“risk” allele in the regulation of PA during chronic pain. The met158 allele has been
associated with incidence of FM (e.g., Garcia-Fructoso et al., 2006; Vargas-Alarcon et al.,
2005), and has also been associated with higher sensory and affective ratings of lab-induced
pain (Zubieta et al., 2003). The met/met genotype has been associated with greater FM
illness severity across domains of pain, fatigue, sleep disturbance, and psychological distress
(Garcia-Fructoso et al., 2006).
The asp-allele of the asn40asp polymorphism in OPRM1 has been reported to result in a
seven to ten-fold reduction in μ-opioid receptor protein in cultured cells (Beyer, Koch,
Schroder, Shulz, & Hollt, 2004; Zhang, Wang, Johnson, Papp, & Sadee, 2005), and is
considered an appropriate candidate for association with pain processing (Uhl et al., 1999).
Despite the relevance of μ-opioid receptor activity to pain processing, the findings from
candidate gene studies have been mixed. Two null findings have been reported in studies of
pain sensitivity (Comptom, Geschwind, & Alarcon, 2003; Kim, Mittal, Iadarola, & Dionne,
2006). In contrast, Fillingim, Kaplan, Staud et al., (2005) reported significant OPRM1
genetic variability in self-reported pressure pain threshold. In that study, individuals with at
least one copy of the minor asp40 allele had a higher pressure (mechanical) pain threshold
than those homozygous for asn40, but the effects did not generalize to other forms of pain
stimuli, including thermal and ischemic pain. There is some evidence in support of
asn40asp-mediated reward processing among people with alcohol abuse problems (Oroszi &
Goldman, 2004), but, to our knowledge, no studies have linked the variant to affective
components of pain.
Given the converging evidence of genetically-regulated, dual-processing neurobiological
pathways of pain and affect, we believe it is appropriate to test for genetic association with
daily affective processes relevant to FM patients. As such, we have centered our focus on
the process of positive affective reactivity to pain. Despite the recent identification of a PA
deficit in FM (Zautra, Fasman, Reich et al., 2005), and replications of those findings (Finan
et al., 2009; Zautra Johnson, & Davis, 2005), there is currently a gap in the knowledge of
what genetic mechanisms may contribute to FM patients’ experience of positive affective
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dysregulation, and how that disturbance may perpetuate and prolong the experience of
chronic pain.
The positive affective response to pain is a salient phenotype that describes a common
affective profile found in FM. Largely missing from the literature of genetic associations in
FM is attention to rich phenotypic assessment that captures the multifarious daily
experiences with chronic pain and affective disturbance. A next step, then, is to examine the
effects of COMT and OPRM1 in the context of PA reports as they occur throughout daily
life in individuals with FM. The examination of naturalistic data extends the laboratory work
that has been integral to our understanding of the influence of the catecholaminergic and
opioidergic systems on these phenotypes, and provides a unique window into the role of
COMT and OPRM1 in the dual processing of pain and affect in the FM condition.
In the current study, we hypothesized that the met158 allele in COMT would be associated
with reduced PA, across 30 days of daily reporting, relative to the val158 allele. Further, we
proposed that a gene × experience effect would be observed, such that individuals with the
met158 allele would suffer a greater reduction in PA on days in which pain was elevated. It
was expected that PA effects would be greater with higher levels of met158 loading. To test
this, trichotomous genotype differences for COMT were examined. In contrast, we
hypothesized that FM patients with the asp40 allele in OPRM1 would have greater PA across
days, and would be better able to sustain PA on days when pain was elevated, relative to
homozygous carriers of asn40.
Method
Participants
The data that were analyzed for the current study were collected as part of a larger project
(R01 AR46034) designed to identify factors related to adaptation to pain and stress in FM.
The larger study included female participants with FM, osteoarthritis, or a dual diagnosis of
both FM and osteoarthritis. Of the 392 participants enrolled in the parent study, 46 qualified
for the current study. 201 individuals were excluded from the current study because they had
a diagnosis of osteoarthritis, 71 individuals were dropped due to an inability to confirm
diagnosis, and 65 participants were dropped for the following reasons: too ill to participate;
no time to participate; changed mind about participation; unable to reestablish contact; upset
about insufficient payment for participation; unable to schedule a mutually convenient time
to meet; and, unknown reasons. Genetic data was unavailable for an additional 7
participants, leaving the final total included in the current study 46. As stated above, only
participants with a single diagnosis of FM were analyzed. This decision was made to
minimize the potential for separate disease processes to confound the analysis of genetic
influences in FM.
Participants were between the ages of 38 and 72 with a physician-confirmed diagnosis FM.
Participants were recruited in the Phoenix, AZ metropolitan area from physician’s offices,
advertisements, senior citizen groups, and mailings to members of the Arthritis Foundation.
Included in the study were participants who had no diagnosed autoimmune or arthritic
disorders, a past-month pain rating above 20 on a 0–100 scale, and/or who were not
involved in litigation regarding their condition. All participants reported their diagnosis to
research staff and subsequently signed a Health Insurance Portability and Accountability Act
(HIPAA) release form. Research staff then contacted each participant’s physician, who sent
a written confirmation of the participant’s FM diagnosis and disconfirmed diagnosis of other
autoimmune and arthritic disorders.
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Procedure
After being screened into the study, participants were visited by a clinician to reconfirm FM
diagnosis. All participants underwent a tender point exam conducted by trained research
personnel supervised by licensed rheumatologists in a method consistent with medical
standards. Our clinician used a dolorimeter to palpate 18 musculoskeletal regions identified
by the American College of Rheumatology as tender points that can aid in FM diagnosis
(Wolfe et al., 1990). The results of the tender point exam were used primarily to identify
outliers whose reported pain may have differed from expectations based on physician
diagnosis. However, results discrepant with diagnostic expectations were not used as
exclusionary criteria. A number of supplementary analyses, described fully in the Results
section, were conducted to examine whether tender point endorsement was influential on the
outcomes of interest in the current study.
After the clinician visit, participants were trained in our laboratory by a research assistant to
use a laptop computer to complete daily diaries each night for 30 days. Participants were
encouraged to call our laboratory staff immediately if a problem occurred with the laptop. A
built-in date-checking software program prevented data entry on days other than the correct
day. After completing the 30-day diary, participants were visited by a clinician, and buccal
cells were collected via a cheek swab method that followed published procedures (Walker et
al., 1999). Participants were compensated $90 for completion of the diary. The overall rate
of diary completion was 92.5%.
Genotyping
Genomic DNA was purified from buccal cheek swab samples by the University of
Connecticut Health Center GCRC Core Lab. DNA samples were placed in 96-well plates
and genotyped using PCR based TaqMan 5’-nuclease allelic discrimination assay methods
in the GCRC Core Lab. Ten percent of genotypes were randomly repeated to monitor
reproducibility. The core lab repeated samples from each plate in a known fashion and
included water blanks and DNA samples with known genotypes to monitor quality control.
Assays for both markers were already in use in the GCRC Core Lab. The primer and probe
combinations for these assays are: COMT val158met polymorphism (rs4680) primers
(CCCAGCGGATGGTGGAT and AACGGGTCAGGCATGCA), and dual labeled probes
(Vic-TCCTTCAcGCCAGCGA-MGB and Fam-TCCTTCAtGCCAGCGA-MGB); OPRM1
Asn40Asp polymorphism (rs1799971) primers (CCCAGCCCCGGTTCCT and
TGATGGCCGTGATCATGGA), and probes (Vic-AGATGGCGACCTGTCC-MGB Fam-
AGATGGCAACCTGTCC-MGB).
Measures
Positive and Negative Affect—PA and NA were measured in the daily diary using the
Positive and Negative Affect Schedule (PANAS; Watson, Clark, & Tellegen, 1988).
Participants rated 10 mood adjectives each for PA and NA using a 5-point scale from 1
(very slightly or not at all) to 5 (extremely). Scores for the two scales were obtained by
computing means, while between-person reliabilities were computed by aggregating each
participant’s items across all days. Cronbach’s alpha was .95 for PA and .86 for NA.
Soft Tissue Pain—The daily diary included a body diagram that depicted the major
quadrants of the body (Affleck et al., 1996), with instructions for participants to rate their
soft tissue pain in 15 areas including parts of their neck, shoulders, chest, arms, legs, back,
and buttocks. Ratings were made on a scale of zero-to-three where zero was “No pain” and a
three meant “Severe pain.” Sum scores were computed from the 15 items to create an
overall score of soft tissue pain. Cronbach’s alpha was .93.
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Interpersonal Stress—Both positive and negative interpersonal life events were assessed
by administering an abridged version of the Inventory of Small Life Events (ISLE; Zautra,
Guarnaccia, & Dohrenwend, 1986). Events were grouped in four domains of the ISLE: a)
friends or acquaintances, b) spouse or partner, c) family members, and d) employment and
co-workers. Participants were first asked to report whether or not each event occurred during
the day of reporting. After responding to each domain of items, participants were asked,
“Overall, how stressful were your relations with your (domain) today?”. Responses were
made on a four-point Likert scale where 1 = Not at all, 2 = A little, 3 = Moderately, and 4 =
Extremely. Stressfulness ratings from each of the four domains were then aggregated to
create a single daily index of perceived stress. This method has been reported elsewhere
(Zautra, Hoffman, Potter et al., 1997).
Data Analysis
The frequencies of the val158met genotypes in COMT have been reported as follows in a
Spanish-origin FM population: [12% (val/val), 51% (val/met), 37% (met/met); Vargas-
Alarcon et al., 2007]. Due to the functionally intermediate action of the heterozygous val/
met genotype, gene effects were expected to be largest for individuals with homozygous
genotypes. No known genotype frequency estimates were available within the FM
population for the asn40asp genotype in the OPRM1 gene. Given the rarity of the
homozygous asp/asp genotype (2–3% in the general population; Ray & Hutchison, 2004),
individuals were analyzed based on the presence or absence of at least one copy of the asp40
allele.
Repeated daily measurements resulted in a hierarchical nested data structure, with up to 30
observations nested within each person. Given such a data structure, multilevel modeling,
executed using SAS PROC MIXED (Littell et al., 1996), was the appropriate data analytic
tool. Predictor variables in the current study were centered within-person (Nezlek, 2001;
Enders & Tofighi, 2007), yielding an index of daily change.
Both Level 1 (within-person) and Level 2 (between-person) variables, as well as cross-level
interactions (Level 1 × Level 2), were modeled as predictors. As an example, we will
highlight the basic equations used in the present study, involving daily PA as the criterion:
(1)
There are i observations of PA for j individuals. β0j yields an estimate of the average level of
PA at the individual’s mean level of pain, when they are experiencing no NA. β1j is the
coefficient for the daily influence of pain on PA and β2j is the coefficient for the relationship
between NA and PA, serving in this model as a covariate. rij is the within-person error
component. At Level 2, individual differences in the average level of PA are probed, along
with cross-level interactions. The Level 2 intercept is specified as follows:
(2)
where the equation for β0j predicts each person’s Level 1 intercept from the grand mean, the
mean level of pain, and the individual’s genotype. The Level 2 slopes are specified as
follows:
(3)
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The second Level 2 equation models a cross-level interaction, whereby between-person
differences in genotype (Level 2) moderate the relationship of within-person changes in pain
(Level 1) and the outcome, daily PA. In all models, a first-order autoregressive variance-
covariance matrix was chosen to model the within-person variance on the dependent
variables, as suggested by Singer (1998). Additionally, because PA and negative affect (NA)
are correlated when pain is elevated (Zautra, Smith, Affleck, & Tennen, 2001), NA was used
as a covariate in all analyses.
Here we are only concerned with fixed effects, and so the Level 2 equations lack a random
error component. Thus, for the analyses presented in the current study, only the intercept
was modeled as random. The decision to model only fixed effects was motivated by the
expectation, supported by the literature, that the gene and gene × experience effect sizes
(typically modeled as “gene × environment” effects in the literature) would be relatively
small. In such cases, it may be considered statistically justifiable to model only fixed effects.
Baseline self-reported medication (anti-inflammatory, muscle-relaxant, opioid-analgesic,
anti-depressant, and anti-anxiety) use was controlled for in all analyses. Ultimately,
medication use was not significantly related to the outcomes and did not alter the results,
and so was left out of the final analyses.
Population stratification is considered a threat to internal validity in association studies
(Cardon & Bell, 2001) and was addressed in the current analyses. Population stratification
occurs when a sample consists of individuals from several different subgroups in which
mating over time has been non-random, potentially having caused intergroup differences in
genotypic representation. To account for this potential threat, ethnic differences were probed
on the primary outcome variable (e.g., PA), and all analyses were re-run excluding non-
Caucasian participants to test the generalizability of the results for Caucasian-only
participants. Due to missing data, when all primary COMT and OPRM1 analyses were re-
run with a Caucasian-only sample, the N decreased from 46 to 35. The result was that
significance estimates varied slightly, but the form and direction of all effects remained
consistent. As a result, we have concluded that there is little evidence to suggest that
population stratification was a threat to the hypotheses tested in the current study.
Results
Participant Characteristics
Participants mean age was 53 (SD=7.82); 93.0% reported Caucasian ethnicity, 67.5% had
completed some college, with 25% holding post-graduate degrees, and 75.7% reported
earning over $30,000 per year, with 41.5% earning over $70,000 per year (demographic data
was missing on six participants). Thus, our sample was of a higher socioeconomic status
than the general FM population (Penrod et al., 2004). All demographic variables were also
tested as predictors of PA and pain among FM patients. However, no significant associations
were found.
The observed genotype frequencies were in Hardy-Weinberg equilibrium, indicating that
non-random selective forces did not bias the genotype distributions. The following genotype
frequencies were observed for the val158met SNP: val/val=12 (26.1%), val/met=24 (52.2%),
met/met=10 (21.7%). The following genotype frequencies were observed for asn40asp
polymorphism: asn/asn=35 (76.1%), asp/asn=10 (21.7%), asp/asp=1 (2.2%). Genotype
frequencies for both polymorphisms resembled population estimates (Ray & Hutchison,
2004; Tiihonen, Hallikainen, Lachman et al., 1999).
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Gene and Gene × Experience Effects on PA
Our approach tested if there were any gene and/or gene × experience effects on PA, as
reported across the span of diary days. COMT and OPRM1 genotypes were not correlated
(r=−.035), so there was no concern that one genotype could confound the effect of the other
genotype on the chosen phenotype. COMT genotype was not associated with PA across
diary days, F(2, 42)=.05, p=.95 (for means and standard deviations, see Table 1). However,
a significant gene × experience interaction was evident, F(2, 1217)=4.49, p<.05 (for
complete multilevel statistics, see Table 2), such that individuals with met/met genotype
experienced a greater decline in PA on days with elevated daily soft tissue pain than did
either val/met or val/val individuals. Examination of the variance components (Singer, 1998)
indicated that the model explained 6% of the within-person variance in PA, with COMT
genotype contributing 1% of variance over and above the effect of pain on PA. The latter
two genotypic groups were not significantly different from each other. Figure 1 depicts the
COMT × daily pain interaction after dichotomizing pain into top and bottom thirds of
responding within the sample. This dichotomization was done for graphical purposes; the
significance of the interaction was still determined based on the coefficient for the
continuous interaction.
To examine the specificity of the effects of COMT on the process of positive affective
reactivity to pain, a regression of daily pain on COMT genotype was performed. No relation
was evident, F(2, 42)=.71, p=.50. Additional analyses revealed useful information pertaining
to the chosen phenotype. First, with regard to the outcome, COMT genotype was not related
to NA across diary days, F(2, 42)=.52, p=.60, and did not interact with daily pain in the
prediction of NA, F (2, 1217)=1.90, p=.15. Second, COMT did not interact with daily
interpersonal stress in the prediction of PA, F(2, 1192)=1.01, p=.36, suggesting that daily
pain was the appropriate predictor. Thus, the influence of COMT did not generalize to other
common daily processes in FM.
OPRM1 genotype evidenced a trend toward a significant prediction of PA across diary days,
F(1, 43)=3.62, p=.06. Patients with an asp40 allele reported higher PA across diary days than
those homozygous for asn40 (for means and standard deviations, see Table 1). The
hypothesis that an OPRM1 × daily pain interaction would be observed was supported, F(1,
1218)=6.06, p<.05 (for complete multilevel statistics, see Table 3). This effect is graphically
displayed in Figure 2. Patients with an asp40 allele experienced a greater decline in PA as
daily soft tissue pain increased than did those carrying two asn40 alleles. Still, as Figure 2
indicates, asp40 carriers reported substantially greater PA than their counterparts on high
pain days. Examination of the variance components indicated that the model explained 6%
of the variance in PA, with OPRM1 genotype contributing 1% of variance over and above
the effect of pain on PA.
A series of analyses were also conducted to examine the specificity of the effect of OPRM1
on positive affective reactivity to pain. First, OPRM1 genotype was not related to daily pain,
F(1, 43)=1.14, p=.29. However, further analyses revealed a significant OPRM1 × daily pain
interaction on NA, F(1, 1218)=5.22, p<.05, such that FM-only asp40 carriers reported a
greater increase in NA as pain increased than those without the asp40 allele. As with COMT,
OPRM1 did not interact with daily interpersonal stress to predict PA, F(1, 1193)=.10, p=.76.
In separate analyses, each genotype was entered as a predictor of both soft tissue pain
variance and PA variance. Met/met individuals evidenced significantly greater soft tissue
pain variance than val/val individuals, F(2, 43)=3.40, p<.05, but did not differ from the
heterozygous genotype. COMT genotype did not predict PA variance across diary days, and
OPRM1 did not predict either pain or PA variance.
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Influence of Tender Point Endorsement
When assessed by trained members of our research staff, some participants endorsed tender
point pain discordant with their physician-confirmed diagnosis. For a diagnosis of FM, pain
should be present in 11 of 18 tender points. Ten FM patients reported pain in fewer than 11
out of 18 tender points. One patient lacked tender point exam data. Ultimately, the
physician-confirmed diagnosis is the gold-standard and was used to classify diagnosis for
the analyses presented above. However, because the present study is concerned with FM-
specific reactivity to daily pain, this finding motivated several tests for the possible
confound of individual differences in tender point endorsement. First, correlations between
tender point endorsement and genotype were examined. Tender point endorsement
evidenced a non-significant trend for a relation to COMT, r=.13, p=.07, and was not
significantly related to OPRM1, r=−.08, p=.26, genotype. Second, all analyses were run
separately including only those FM patients who reported pain in 11 or more tender points.
Results of these separate analyses did not significantly differ from results run with the full
sample. Finally, the number of tender points endorsed was included as a covariate in
analyses involving the full sample of FM patients. No effects were significantly altered
through the inclusion of raw tender point endorsement as a covariate. Thus, it is unlikely that
individual differences in tender point endorsement affected any of the present results.
Discussion
The purpose of the present study was to test the relation of candidate genes from the
catecholaminergic and opioidergic systems to positive affective regulation during pain. As
hypothesized, COMT moderated the relation of daily pain to daily PA such that elevations in
pain were associated with lower PA to a greater degree among met/met individuals than their
val/met and val/val counterparts. A gene-dose effect was not observed, as the heterozygous
group closely resembled the homozygous val/val group. This finding suggests that the lower
enzymatic activity on catecholamines conferred by the met/met genotype affects FM
patients’ ability to maintain PA in the face of pain flares. Importantly, this finding stands in
contrast to Zubieta et al.’s (2003) finding that COMT was not associated with the positive
affective components of pain. The current study differs in sample constituency (FM patients
vs. normative population), methodology (daily diary vs. laboratory pain manipulation), and
measurement (PANAS vs. McGill Pain Questionnaire), and so comparing results must be
qualified by those major differences. Still, the contrast offers a chance to highlight the
potential role for COMT in the concomitant PA deficit with widespread pain in FM. Broadly
speaking, the results suggest that the association of COMT and pain is variable and context-
dependent.
Both gene and gene × experience effects on daily PA were found for OPRM1. FM patients
with at least one asp40 allele reported more PA across diary days than those homozygous for
asn40, although this was only a trend (p<.06). On days when pain was elevated, however,
asp40 individuals report a greater decrease in PA than those homozygous for asn40. There is
more than one possible explanation for this finding. One possibility is that asp40 individuals
experience more PA, in general, than their counterparts, but face greater instability in their
positive affective reactivity to pain. An alternate interpretation could be that the average PA
level for asn40 individuals is so low that elevations in pain will not appreciably change that
level. The likelihood of this possibility is bolstered by the comparison of PA levels in past
studies using a similar sample. For example, Zautra et al. (2005) reported an average PA
level of 2.78 (SD=.58) for the FM patients in that study. In comparison, the FM patients
homozygous for asn40 in the current study reported a mean PA level across days of 2.26
(SD=.74). Thus, the average PA level experienced by homozygous asn40 carriers was low,
even relative to those of other FM samples. This suggests that there may have been little
room for those individuals to decline in PA on days of elevated pain. Either way, the
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findings suggest that the asp40 allele may be a source of resilience for FM patients. Even on
high pain days, they are able to maintain higher PA levels than those of their counterparts.
For both the COMT and OPRM1 interaction effects, genotype explained just 1% of the
variance over and above the effect of pain on PA. Although these are small effects, they are
consistent with the size of effects generally reported in the gene × environment literature,
which can be considered a useful comparator to the findings presented here. Further, effect
sizes in daily diary studies should be interpreted in the context from which they are derived;
small effects compounded daily over time may have greater long-term significance than can
be measured by a traditional effect size estimate.
Genotypic differences emerged in the day-to-day variance of pain reports, such that met/met
individuals evidenced significantly greater daily variance in their pain scores than those with
the val/val genotype. How does this between-genotype difference relate to the finding that
met/met individuals experienced less PA on days in which pain was elevated? It is possible,
although speculative, that the greater daily variability in pain experiences for the met/met
group led them to show more pronounced positive affective responses to pain elevations.
The met/met group did not significantly differ from other COMT genotypes in daily PA
variance, suggesting that their more highly variable pain scores could have influenced their
relatively stable PA variance. Further evidence through direct testing will be needed to
explicate these potential relations.
Our confidence in these findings is strengthened by the results of analyses that controlled for
the influence of tender point pain on PA. Contrary to diagnostic criteria, about 23% of FM
patients endorsed pain in fewer than the minimum 11 tender points needed to meet
conditions for diagnosis. Still, despite controlling for the discrepant tender point
endorsements in our analyses, the primary gene and gene × experience findings remained.
That the effects of COMT and OPRM1 were observed among FM patients with and without
the requisite number of tender points suggests that factors other than widespread pain may
serve to cluster these individuals. This result supports recent assertions (Finan et al., 2009)
that the diagnosis of FM may require a broader assessment than that put forth by the
American College of Rheumatology (Wolfe et al., 1991).
A major strength of the current study is the attention to rich phenotypic measurement, a
focus that is often absent from behavioral genetic research in chronic pain. An approach that
emphasizes a case-control design fails to take into account the heterogeneity of symptoms
within the FM population and the variable process of adaptation to pain and stress that
occurs daily. A naturalistic phenotype approach, in which genetic association can be
explored within the context of daily processes relevant to a disease, allows for greater
flexibility in the choice of phenotype. Analyses in the present study revealed that, by and
large, daily positive affective reactivity to pain was an appropriate phenotype with variation
that can be explained by variation in both COMT and OPRM1. That neither COMT nor
OPRM1 were related to positive affective reactivity to stress suggests that the phenotype of
reactivity to pain appropriately approximated the neurobiological functions of the genes.
Even more, COMT did not moderate the relation of pain to NA, providing further support
for the specificity of the phenotype. The finding that OPRM1 genotype significantly
moderated negative affective reactivity to pain suggests that more work must be done to
refine this phenotype.
Relatively little empirical work has been directed toward elaborating phenotypes that
reliably capture the wide variety of symptoms experienced by FM patients, including mood,
fatigue, interpersonal instability, and stress reactivity. The current study capitalized on the
methodological strength of the daily process design, which increases the power to detect
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small effects through reliable, repeated measurement. It is quite possible that a cross-
sectional design with a similarly small sample size might not have detected the gene ×
experience effects observed in the current study. Thus, the current study highlights the utility
in robust phenotypic measurement for clinical researchers interested in explicating the
influence of genomic variants in complex chronic pain disorders with psychopathological
comorbidities.
We prefer a cautious approach in discussing the implications of the gene × experience
effects for diagnosis and treatment. No conclusions should be made in that regard until these
findings are replicated in a different sample with more participants. If the findings are
replicated, clinical trials might be warranted to determine if FM patients of certain
genotypes respond more favorably to one treatment approach versus another.
Limitations
One major limitation of the current study was the single SNP approach inherent in its
design. Enthusiasm over this approach has been recently tempered by the glut of small effect
sizes and non-replications, as well as the potential utility of functional gene networks. Other
currently available approaches could certainly expand the knowledge gained from the
current study. For example, the haplotype approach, used in identifying COMT-moderated
pain sensitivity by Diatchenko, Slade, Nackley et al. (2005), allows for the grouping of
multiple SNPs to be analyzed based on their cumulative contribution to a behavioral
phenotype. Diatchenko et al.’s work shows that it may not be the met158 allele, alone, that
accounts for pain sensitivity, but rather a combined effect of that allele with alleles from
SNPs in high linkage disequilibrium with val158met.
Second, the current study included only female participants. Although FM primarily affects
women, gender differences are widely reported in candidate gene studies, and a male
comparison group may have provided important information about genetic differences in
dynamics of pain and affect. Future studies should include a male cohort to determine if the
present findings are moderated by gender.
Third, due to the small sample, the varying reports of tender point pain, and the trend
observed between tender point endorsement and COMT genotype, we cannot exclude the
possibility that tender point pain may have been related to genotype, and may have
influenced the primary findings. A larger sample will be needed to confidently dismiss this
possible confounding relation.
Finally, it remains to be seen if the findings in the current study generalize beyond FM
patients. The sample was recruited with some criteria (e.g. absence of other rheumatic
diagnosis) that may limit the relevance of the current findings to other FM populations. The
concept of dual processing of pain and emotion is relevant to other chronic pain groups. The
analyses presented in this manuscript will need to be tested on other populations before
conclusions can be made about whether the findings are specific to FM patients or common
across chronic pain patients in general.
Summary and Conclusions
Evidence has been provided in support of the hypotheses that variants in COMT and
OPRM1 would be associated with the dual processes of pain and affect in FM. The findings
are unique in several respects. First, they make use of repeated measurements of pain and
affect collected across 30 days of electronic diary entries. This methodology allowed for the
examination of genetic associations with a stable PA phenotype, observed over time, as well
as positive affective reactivity to naturally occurring perturbations in pain. Naturalistic data
such as those presented in the current study are crucial to our understanding of FM because
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pain for this patient population is often closely related to life stress and interpersonal
processes that are, at best, imperfectly simulated in the laboratory. By identifying two
separate, but complimentary, neurobiological systems that have been shown to contribute to
pain and affective processing, the current study sought to determine if candidate genes
known to have regulatory roles within those systems were associated with a dual processing
model of pain-related positive affective regulation in FM. To that end, hypotheses that the
val158met polymorphism in COMT and the asn40asp polymorphism in OPRM1 would be
associated with daily positive affective reactivity to pain, were supported. The findings offer
researchers ample reason to further investigate the contribution of the catecholamine and
opioid systems, and their associated genomic variants, to the still poorly understood
experience of FM.
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Figure 1. COMT × pain interaction
Slopes reflect positive affective reactivity to high versus low pain days for patients with
either val/val, val/met, or met/met genotypes. X-axis parameters were generated by
dichotomizing centered pain scores into the top and bottom third of responses across
participants.
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Figure 2. OPRM1 × pain interaction
Slopes reflect positive affective reactivity to high and low pain days for patients who are
either carriers or not carriers of the asp allele. X-axis parameters were generated by
dichotomizing centered pain scores into the top and bottom third of responses across
participants.
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Table 1
Means and Standard Deviations of Positive Affect by Genotype
Fibromyalgia Patients
N=46
Catechol-O-Methyltransferase M SD
val/val 2.43a .73
val/met 2.37a .83
met/met 2.37a .98
μ-Opioid Receptor
asp-carrier 2.78a .80
asn/asn 2.26b .74
Note. Means and standard deviations are provided for positive affect, aggregated across diary days. Comparisons were made between genotype,
and values in each column (separately, for each gene) that do not share a common superscript are significantly different from each other, p<.05.
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